Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CIGB 300

Next Previous
X
Search
Drug Profile

CIGB 300

Alternative Names: CIGB-300; IGBC-300; P15-Tat

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Elea; Heber Biotec
  • Class Antineoplastics; Apoptosis regulatory proteins; Immunotherapies; Peptides
  • Mechanism of Action Apoptosis stimulants; Casein kinase II inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II/III Condylomata acuminata
  • Phase II Cervical cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes
  • No development reported Breast cancer

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Breast-cancer in Cuba (IV)
  • 30 Jul 2020 Center for Genetic Engineering and Biotechnology plans a phase I/II trial for COVID-19 infections (Combination therapy) in Cuba (IV) (RPCEC00000317)
  • 21 Apr 2018 Preclinical trials in Breast cancer in Cuba (IV) prior to 21/04/2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top